Immuno-oncology therapy in metastatic bladder cancer: A systematic review and network meta-analysis

阿替唑单抗 彭布罗利珠单抗 医学 杜瓦卢马布 肿瘤科 养生 内科学 不利影响 阿维鲁单抗 免疫疗法 癌症
作者
Francesco Chierigo,Mike Wenzel,Christoph Würnschimmel,Rocco Simone Flammia,Benedikt Horlemann,Zhe Tian,Fred Saad,Felix K. H. Chun,Derya Tilki,Shahrokh F. Shariat,Michele Gallucci,Marco Borghesi,Nazareno Suardi,Carlo Terrone,Pierre I. Karakiewicz
出处
期刊:Critical Reviews in Oncology Hematology [Elsevier BV]
卷期号:169: 103534-103534 被引量:7
标识
DOI:10.1016/j.critrevonc.2021.103534
摘要

Three first line and three second-line clinical trials tested the effect of immunotherapy (IO) relative to standard chemotherapy (CT) on overall survival. However, network meta-analysis-based comparisons have not yet been presented. We addressed this void.To provide comparisons of overall survival (OS), progression-free survival (PFS), complete response (CR), partial response (PR), stable disease (SD), objective response rates (ORR), disease control rates (DCR) and adverse events (AEs) associated with 1st and 2nd line IO-based regimens.PubMed was searched for phase III randomized controlled trials from 2016 to 2021, including conference abstracts. We identified three first line [IMvigor130 (atezolizumab + CT vs atezolizumab vs CT), DANUBE (durvalumab vs durvalumab + tremelimumab vs CT), and KEYNOTE-361 (pembrolizumab + CT vs pembrolizumab vs CT)] and two second line [KEYNOTE-045 (pembrolizumab vs CT) and IMvigor211 (atezolizumab vs CT)] RCTs.Overall, 3255 and 1452 patients were respectively included in the first- and second-line settings. In 1st line setting, compared with CT, no IO-based regimen exhibited survival benefit. However, all exclusive IO regimens resulted in lower rates of grade 3+ AEs. In 2nd line setting, compared with CT, only pembrolizumab improved OS benefit. Conversely, atezolizumab only showed OS benefit in exploratory analyses. Compared to second-line CT, no experimental regimen (atezolizumab or pembrolizumab) exhibited statistically significant ORR benefit. Both pembrolizumab and atezolizumab resulted in lower rates of grade 3+ AEs compared to 2nd line CT.In metastatic UC, IO-based regimens do not hold a survival benefit relative to CT in 1st line setting. However, pembrolizumab holds a survival benefit in 2nd line compared to CT. Several IO-based clinical trials are ongoing and will provide more and possibly better treatment alternatives for locally advanced and metastatic UC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
lvsehx发布了新的文献求助10
4秒前
热情思天完成签到,获得积分10
5秒前
阳和启蛰完成签到 ,获得积分10
8秒前
123321完成签到 ,获得积分10
9秒前
小彤完成签到 ,获得积分10
9秒前
CodeCraft应助lumia采纳,获得10
9秒前
guoguo完成签到 ,获得积分10
13秒前
大坚果发布了新的文献求助10
15秒前
杨。。完成签到 ,获得积分10
19秒前
郭泓嵩完成签到,获得积分10
20秒前
香蕉觅云应助ze采纳,获得10
20秒前
风一样的我完成签到,获得积分10
20秒前
猪肉超人菜婴蚊完成签到,获得积分10
26秒前
打打应助冯昊采纳,获得10
28秒前
大个应助丸子_2025000采纳,获得10
31秒前
传奇3应助lvsehx采纳,获得10
31秒前
小二郎应助yuqinghui98采纳,获得10
33秒前
科目三应助婷婷采纳,获得10
34秒前
34秒前
Herisland完成签到 ,获得积分10
34秒前
35秒前
36秒前
39秒前
kun完成签到 ,获得积分10
39秒前
ze发布了新的文献求助10
39秒前
冯昊发布了新的文献求助10
40秒前
安安发布了新的文献求助10
41秒前
大恐龙完成签到,获得积分10
41秒前
1111chen发布了新的文献求助10
44秒前
蓝色白羊完成签到,获得积分10
45秒前
聪明平灵完成签到,获得积分10
45秒前
45秒前
47秒前
婷婷发布了新的文献求助10
48秒前
ze完成签到,获得积分20
48秒前
任性的凝云完成签到,获得积分10
49秒前
1111chen完成签到 ,获得积分10
51秒前
小二郎应助聪明平灵采纳,获得10
51秒前
00完成签到,获得积分10
51秒前
高分求助中
【此为提示信息,请勿应助】请按要求发布求助,避免被关 20000
Production Logging: Theoretical and Interpretive Elements 3000
CRC Handbook of Chemistry and Physics 104th edition 1000
Izeltabart tapatansine - AdisInsight 600
Introduction to Comparative Public Administration Administrative Systems and Reforms in Europe, Third Edition 3rd edition 500
Distinct Aggregation Behaviors and Rheological Responses of Two Terminally Functionalized Polyisoprenes with Different Quadruple Hydrogen Bonding Motifs 450
Individualized positive end-expiratory pressure in laparoscopic surgery: a randomized controlled trial 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3761753
求助须知:如何正确求助?哪些是违规求助? 3305518
关于积分的说明 10134626
捐赠科研通 3019564
什么是DOI,文献DOI怎么找? 1658226
邀请新用户注册赠送积分活动 791974
科研通“疑难数据库(出版商)”最低求助积分说明 754751